NCT02720874 (MAPPIT-RA) is a NA clinical trial of Rheumatoid arthritis educational booklet in Arthritis, Rheumatoid, sponsored by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center.

What drugs are being tested in NCT02720874?

Interventions in NCT02720874: Rheumatoid arthritis educational booklet, Multidisciplinary rheumatologic care, Nurse education and monthly calls, Monthly healthcare coordinator calls, Technology-based symptom monitoring and reporting.

What condition does NCT02720874 study?

NCT02720874 studies Arthritis, Rheumatoid.

Is NCT02720874 still recruiting?

NCT02720874 is currently withdrawn. Last updated 9 March 2026.

Last reviewed 2026-03-09 · How we verify

NCT02720874: MAPPIT-RA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Multidisciplinary Approach for Treat To Target In Rheumatoid Arthritis

Withdrawn NA Last updated 9 March 2026

What this trial tests

NA trial testing Rheumatoid arthritis educational booklet in Arthritis, Rheumatoid. Withdrawn.

Timeline

1 January 2025

Primary endpoint
14 April 2025

14 April 2025

Quick facts

Lead sponsor	Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	1 January 2025
Primary completion	14 April 2025
Estimated completion	14 April 2025
Sites	1 location across United States

Drugs / interventions tested

Rheumatoid arthritis educational booklet
Multidisciplinary rheumatologic care
Nurse education and monthly calls
Monthly healthcare coordinator calls
Technology-based symptom monitoring and reporting

Conditions studied

Arthritis, Rheumatoid — all drugs for Arthritis, Rheumatoid →

Sponsor

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Who can join

18 and older, any sex, with Arthritis, Rheumatoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This research will evaluate a multifaceted patient-centered intervention in a sample of socioeconomically disadvantaged Hispanic adults with rheumatoid arthritis (RA) that capitalizes on a partnership between the extended rheumatology healthcare team and each patient in order to promote understanding, uptake and adherence to the principles of treat-to-target strategy. The primary hypothesis of this study is that the addition of a multifaceted intervention incorporating integrated multidisciplinary rheumatologic care, nurse-directed self-management education and supportive follow-up, and technology-based at home RA symptom monitoring and reporting to clinical guideline-based care will increase RA remission rate at 6 months.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[Telemedical care and IT-based systems in rheumatology].
McCutchan R, Bosch P. · · 2021 · PMID 34618209 · DOI 10.1007/s00393-021-01098-w

Verify or expand the search:

Other recruiting trials for Arthritis, Rheumatoid

Currently open trials in the same condition.

NCT07176390 — A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) · Phase 2 · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06528431 — Design and Evaluation of an Individualized Biodrug Tapering Strategy Based on Biodrug Dosage: the MONITORA Study · Phase 4 · recruiting
NCT06492200 — Impact of a High-fiber Diet on the Microbiome and Disease Activity in Patients With Rheumatoid Arthritis · NA · recruiting
NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting

Other Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center trials

Trials by the same sponsor.

NCT04526860 — Determine if Human Infant Weight Gain Can be Modulated to Prevent Obesity · NA · withdrawn
NCT04918719 — Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke · Phase 2 · completed
NCT06342609 — Effect of Colchicine on Progression of Known Coronary Atherosclerosis in Patients With Stable Coronary Artery Disease · Phase 4 · completed
NCT05398692 — Long COVID-19 Rehabilitation & Recovery Research Program · NA · terminated
NCT04782063 — Prevention of Obesity in Infants of Overweight and Obese Women · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02720874 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Last refreshed: 9 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02720874.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing